NORTH American pharmaceutical-grade medicinal cannabis producer Tilray, the first to be certified in accordance with the European Medicines Agency's (EMA) Good Manufacturing Practice (GMP), announced that it had successfully exported medical cannabis products to Victoria, Australia.
According to the Victorian Government, 29 critically ill children will become the first patients in the state to legally access medical cannabis when the Tilray products are distributed.
"This is too important to wait. That's why we're doing everything we can to make sure those families in the greatest need can access this life-changing treatment for their kids as soon as possible," said Premier Daniel Andrews.
"This is the first time in Victoria kids with severe epilepsy will be able to legally access medicinal cannabis," he said.
Tilray products are currently available to certain patients in other Australian states and in New Zealand under special access pathways for unapproved medicines.
Tilray has exploded to become a leading global supplier of pharmaceutical-grade medical cannabis products including whole flower, oils and capsules for commercial, compassionate access and research purposes, through Canada, European Union, New Zealand and Latin America.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Mar 17
